Thalia Therapeutics Acquires Sanmirna and Raises £2.75M to Advance Phase 1 AML RNA Therapy

Thalia Therapeutics has used this RNS to do two things at once – buy a clinical-stage oncology asset and raise fresh cash to push it forward. For retail investors, that makes this a genuine strategy reset rather than a routine AIM fundraise.

In plain English, Thalia is moving faster into human-stage drug development by acquiring Sanmirna Therapeutics and its Acute Myeloid Leukaemia, or AML, candidate miRisten. That is a bigger, bolder story than being mainly a delivery technology and preclinical RNA business, but it also brings more dilution, more execution risk and a few governance questions that investors should not ignore.

Thalia Therapeutics Sanmirna acquisition explained in plain English

Thalia is acquiring Sanmirna Therapeutics Inc, a US biotech whose main asset is an exclusive licence to miRisten from City of Hope. Sanmirna has no revenues, according to the RNS, so investors are really buying into the licence, the know-how and the ongoing Phase 1 trial rather than an established trading business.

The initial consideration is £3.675 million, with up to £13 million more payable if development, regulatory and sales milestones are met. That means the headline potential price can rise to £16.675 million, before taking into account up to US$1.2 million of City of Hope Phase 1 trial funding that may be reimbursed within five years.

The important bit is what Thalia gets on day one. It becomes a clinical-stage RNA therapeutics company immediately, because miRisten is already in a Phase 1 trial in relapsed or refractory AML patients, with top-line data expected in H1 2027.

Key numbers from the Thalia £2.75 million fundraise and Sanmirna deal

Item	Detail
Fundraise size	£2.75 million
Issue price	0.6p per share
New fundraise shares	458,333,333
Initial acquisition consideration	£3.675 million
Deferred consideration	Up to £13 million
Consideration shares	485,107,215
Convertible Loan Note	£764,357
Director subscriptions	£1,117,500
Directors and vendors subscribing	£1,292,500
miRisten Phase 1 funding from proceeds	£1.0 million
Cardiovascular asset funding	£0.75 million
Working capital, further R&D and costs	£1.0 million

The fundraise was done at 0.6p a share and, notably, at a premium to the previous day’s closing price. The RNS does not disclose that closing price, but raising at a premium is usually a healthier sign than a deeply discounted placing, especially on AIM.

It was also described as oversubscribed, which means investor demand exceeded the number of shares available. That is another positive signal, and the participation from directors and vendors adds a bit more weight behind the story.

Why miRisten could materially change the Thalia investment case

miRisten is a microRNA, or miRNA, therapeutic candidate designed to inhibit miRNA-126, which Thalia says is believed to play a critical oncogenic role in AML. In simple terms, the company is targeting a small RNA molecule involved in cancer biology, rather than using a standard chemotherapy approach.

Why does that matter? Because Thalia’s existing story was largely about earlier-stage RNA assets and delivery technology, including Nuvec® and a preclinical bispecific siRNA programme. A clinical-stage asset brings nearer-term news flow, and in small biotech that can radically change how the market values a business.

AML is also a serious indication. The RNS describes it as a rare and aggressive blood cancer affecting more than 22,000 new US patients annually, with a market opportunity of US$3.9 billion projected to grow to US$9.8 billion by 2035.

That said, this is still early-stage biotech. Phase 1 is primarily about safety and early signs of efficacy, not proof that a drug will make it all the way to market. The opportunity is large, but so is the development risk.

What is good news in this Thalia RNS for AIM investors

The strongest positive here is the move into the clinic. Investors now have a clearer catalyst in H1 2027, when top-line Phase 1 data is due, rather than waiting on a purely preclinical timetable that can often drift.

Second, the fundraise appears to cover a meaningful work programme through mid-2027. The money is earmarked not just for miRisten, but also for Thalia’s cardiovascular programme and general working capital, which helps the company avoid becoming a one-asset punt overnight.

Third, insider support is real. Directors subscribed for £1,117,500, representing 40.1% of the total fundraise, and directors plus vendors subscribed for £1,292,500. That does not eliminate risk, but it does show the people closest to the deal are putting money in.

The lock-in terms help too. The initial consideration shares, and any fundraise shares held by vendors, are locked in for 12 months and then subject to an orderly market agreement for a further 12 months. That reduces the immediate fear of a big stock overhang hitting the market.

The risks: dilution, milestone payments and the David Solomon related-party issue

Let’s not sugar-coat it – this is a heavily equity-funded deal. Thalia is issuing 458,333,333 new fundraise shares, plus 485,107,215 consideration shares, with the possibility of more shares later through the convertible loan note and Milestone 1 consideration structure.

That means dilution for existing shareholders. If the acquired asset works, that dilution may be worth it. If it does not, investors will have given up a lot of equity for a failed clinical punt.

There is also a related-party angle. Chief executive David Solomon is the sole director of Sanmirna and, before completion, will hold about 19% of Sanmirna. Because of that, part of the transaction involves him receiving around £700,159 in convertible loan notes, and he may also receive around 19% of any deferred consideration that becomes payable.

The independent directors say the terms are fair and reasonable, having consulted with the nominated adviser. That is important, but investors should still keep an extra eye on governance whenever the chief executive is effectively on both sides of a transaction.

What Thalia shareholders should watch next before and after the AGM

The deal is conditional on shareholder approval at the AGM on 17 July 2026. So this is not done and dusted yet, although completion is expected if the resolutions pass.

The first batch of fundraise shares is expected to start trading on 30 June 2026. Admission of the second fundraise shares and the consideration shares is expected on 20 July 2026, subject to approval.

Beyond that, the main value driver is simple: can miRisten deliver credible Phase 1 data in AML by H1 2027? If it can, Thalia will look smart for buying time and clinical progress. If not, this RNS may end up reading like an expensive detour.

My take on whether this Thalia acquisition and fundraise is positive

On balance, I think this is strategically positive. Thalia has bought itself a faster route to relevance by adding a clinical-stage cancer asset, and the premium-priced, oversubscribed fundraise suggests the market was willing to back that shift.

But this is not a low-risk upgrade. It is a classic small-cap biotech trade-off: more excitement, more potential upside, and much more clinical and dilution risk. For shareholders, the story is better than it was yesterday – just not safer.